Karim Shalaby - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Karim Shalaby

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

International Journal of Molecular Sciences|October 8, 2020

Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral VectorsKarim Shalaby, Mustapha Aouida, Omar El-Agnaf

Paediatric Respiratory Reviews|June 27, 2006

Immunotherapy as a disease modifierJames G Martin, Karim Shalaby, Marie-Claire Michoud

Proceedings of the National Academy of Sciences of the United States of America|May 7, 2014

NLRX1 prevents mitochondrial induced apoptosis and enhances macrophage antiviral immunity by interacting with influenza virus PB1-F2 proteinJoanna Jaworska, François Coulombe, Jeffrey Downey, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

International Journal of Molecular Sciences|October 8, 2020

Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral VectorsKarim Shalaby, Mustapha Aouida, Omar El-Agnaf

Paediatric Respiratory Reviews|June 27, 2006

Immunotherapy as a disease modifierJames G Martin, Karim Shalaby, Marie-Claire Michoud

Proceedings of the National Academy of Sciences of the United States of America|May 7, 2014

NLRX1 prevents mitochondrial induced apoptosis and enhances macrophage antiviral immunity by interacting with influenza virus PB1-F2 proteinJoanna Jaworska, François Coulombe, Jeffrey Downey, et al.

Pageof 1